Navigation Links
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Date:6/1/2009

ivate the T cells of a patient's immune system to eliminate cancer cells. Four of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Adecatumumab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer.

In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma. Micromet
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
2. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
3. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
5. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
6. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
7. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
8. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
11. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015 The Pistoia Alliance, a global, ... to lower barriers to innovation in R&D, has announced ... , The Ontologies Mapping project has been set up ... ontology management in life sciences R&D. The project will ... guidelines, tools and services to enable the universal application ...
(Date:4/28/2015)... 2015 uBiome, Inc. has announced ... provide clinical tests based on its unique microbial ... startup sparked the era of microbiome-based personalized medicine ... accessible information about their own bodies using the ... microbiome. uBiome has gathered millions of data points ...
(Date:4/28/2015)... More than 50% of patients with ... over the course of their disease, and clinicians are ... the disease progresses. ReachMD , the 24/7 health ... a series dedicated to PD psychosis, featuring interviews and ... and psychiatric conditions. , The new series titled ...
(Date:4/28/2015)... April 28, 2015 IMS is ... bring it to the web and provide greater ... user friendly reporting metrics increase data warehouse’s utility; ... convenient recall and access “on-the-go” makes data analysis ... using client feedback to assist in repository analytics ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2uBiome Launches Clinical Laboratory 2ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2
... Wis. Berbee Information Networks Corporation , a ... & Solutions LLC for an undisclosed sum. , ,Berbee said ... firm, bringing it to about 630 employees in all. Strategies ... IBM's iSeries line of business servers. , ,Berbee has ...
... new version of its Mediasite presentation recorder for the Japanese ... date and hopes to create a bigger market. , ,Mediasite ... as a PowerPoint deck with a video of the speaker ... , ,According to company statements the Japanese market is attractive ...
... Manufacturing Company in Racine is providing heat-transfer components ... , the company said on Wednesday. , ,The parts ... company's new hybrid vehicle. Modine's mass heat transfer ... which is the car's main energy source. , ,The ...
Cached Biology Technology:Modine explores making components for fuel cell vehicles 2Modine explores making components for fuel cell vehicles 3
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... thrive in extreme situations---surviving on toxic chemicals, for instance. ... the American Chemical Society (JACS) May 25, University of ... that: by harnessing other potentially harmful chemicals known as ... , Such insights could lead to new ways of ...
... determined the first detailed molecular images of a piece of ... host cells and initiate the first stages of infection. The ... may help scientists learn new details about how the virus ... potential weak points that can be exploited by novel antiviral ...
... Albert Einstein College of Medicine have discovered a novel ... soon be able to resist the effects of antibiotics ... microbes, including Shigella and E. coli, are rapidly becoming ... led by Dr. John S. Blanchard, the Dan Danciger ...
Cached Biology News:A radical solution for environmental pollution 2Learning how SARS spikes its quarry 2Learning how SARS spikes its quarry 3Einstein researchers identify new way that bacteria develop resistance to antibiotics 2